Marinus Pharma (MRNS) Announces Proposed Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Marinus Pharmaceuticals (MRNS) PT Lowered to $22 at Jefferies
November 9, 2022 8:04 AM ESTJefferies analyst Andrew Tsai lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $22.00 (from $29.00) while maintaining a Buy rating.
The analyst commented, "We think the ongoing launch of Ztalmy (oral ganaxolone; GNX) in CDD rare-epilepsy ($100M+ peak sales) is executing... More
